Stockreport

IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager

IN8bio, Inc.  (INAB) 
PDF $20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“?d”) T cell engager through an Investigational Ne [Read more]